Lilly Evista DTC Ad Depiction of Osteoporosis Severity Draws FDA Objection
Executive Summary
A direct-to-consumer broadcast ad for Lilly's osteoporosis therapy Evista "broadens" its patient population by implying all women will develop osteoporosis at menopause, FDA's Division of Drug Marketing, Advertising & Communications said.